[Comparative evaluation of the anti-anginal effects of dilzem and corinfar in patients with ischemic heart disease and exertion-induced stenocardia].
Antianginal efficiency of dilzem, as compared to placebo, was assessed in 53 patients with angina of effort, functional class II-IV. Repeated bicycle ergometry and 24-hour ECG monitoring were used as objective methods for the assessment of treatment efficiency. Antianginal effect of dilzem (180-300 mg/daily) was compared to that of corinfar (30-60 mg/daily) in 16 patients by a simple blind cross procedure, using placebo. The duration of continuous bicycle ergometric exercise increased by 163 sec. In the presence of dilzem, and by 152 sec. in the presence of corinfar, as compared to the placebo, while the performance volume increased by 1296 and 1188 kgm, respectively (p less than 0.001). Unlike corinfar, dilzem produced a significant drop in heart rate and double product both at rest and during exercise. Both dilzem and corinfar considerably reduced average rate and total duration of painless episodes of myocardial ischemia (p less than 0.05), as evidenced by Holter's monitoring.